Core Insights - BioHarvest Sciences Inc has completed the first stage of a multi-phase development program focused on a rare scent-producing plant for the global fragrance industry [1] - The successful creation of a stable cell culture for this endangered plant species allows for the production of valuable fragrance compounds without harvesting from its natural habitat [2] - The company aims to enter the premium fragrance segment, estimated at $23 billion within the $58.9 billion global fragrance market [3] Development and Technology - The proprietary Botanical Synthesis platform was utilized to replicate the plant's molecular composition, identifying key compounds significant for perfumery [4] - The achievement demonstrates the capabilities of the Botanical Synthesis platform and reinforces the company's royalty-driven CDMO model [6] Business Model and Partnerships - BioHarvest retains a 20% ownership stake in the compositions developed, allowing participation in potential downstream revenues [6] - The project reflects a shift towards a partner development and manufacturing organization (PDMO) model, emphasizing shared value creation [6] Future Plans - With Stage 1 complete, the company plans to move into Stage 2, focusing on scaling production to generate biomass, with pre-commercial testing material expected in six to nine months [8] - The project may serve as a model for future programs targeting other rare and high-value fragrance plants, expanding opportunities within the CDMO division [9]

Core Insights - Riverwater Partners' Small Cap Strategy underperformed the Russell 2000 Index in Q4 2025 and for the entire fiscal year 2025, primarily due to stock selection and an emphasis on high-quality stocks that lagged behind broader market trends [1] - The firm anticipates a more favorable environment for high-quality businesses in 2026 [1] Company Highlights - BioHarvest Sciences Inc. (NASDAQ:BHST) is a biotechnology company focused on developing technology for higher concentrations of active ingredients from plant cells [2] - Over the past 52 weeks, BioHarvest Sciences Inc. shares traded between $4.72 and $12.80, closing at $5.77 on January 22, 2026, with a one-month return of 8.26% but a three-month loss of 49.87% [2] - The market capitalization of BioHarvest Sciences Inc. is approximately $130.788 million [2] Investment Strategy - Riverwater Partners initiated a position in BioHarvest Sciences Inc. during Q4 2025, having monitored the company for about 18 months and engaged in multiple meetings with its CEO [3] - The firm participated in a recent secondary offering of BioHarvest Sciences Inc. at a discount to its trading valuation, highlighting the attractiveness of its Botanical Synthesis platform for sustainable production of plant phytochemicals [3] - BioHarvest Sciences Inc. currently generates revenue from its VINIA nutraceuticals franchise, which utilizes resveratrol from grapes for health benefits, and the firm plans to increase its position over the next 6–12 months as the company executes its growth plan [3]